AstraZeneca PLC announced that it will present new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer, 28 to 31 January 2021. Eleven AstraZeneca medicines and potential new medicines from the pipeline feature in 39 abstracts showcasing the Company’s leadership across different types and stages of lung cancer, including eight oral presentations with two late breakers. Presentations include: Updated data from the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan (Dato-DXd; DS-1062) with additional patients, supporting its potential to redefine treatment outcomes in advanced non-small cell lung cancer (NSCLC) Datopotamab deruxtecan is a novel trophoblast cell-surface antigen 2 (TROP2)-directedantibody drug conjugate (ADC). New data from the DESTINY-Lung01 Phase II trial highlighting the potential of ENHERTU®(trastuzumab deruxtecan) in HER2-expressing metastatic NSCLC, and data in metastatic HER2-mutant (HER2m) NSCLC, two groups of patients for whom no HER2-directed medicine is currently approved. New analyses from the ADAURA Phase III trial featured in two oral presentations reinforcing the unprecedented benefit of TAGRISSO® (osimertinib) regardless of prior adjuvant chemotherapy or disease stage in the adjuvant treatment of epidermal growth factor receptor-mutated (EGFRm) NSCLC, and showing patients treated with TAGRISSOmaintained their quality of life Updated data from the TROPION-PanTumor01 Phase I trial of the novel ADC datopotamab deruxtecan will be featured in an oral presentation, demonstrating early antitumor activity in patients with advanced/metastatic NSCLC who had progressed on standard treatment. Additionally, two presentations on the data from the DESTINY-Lung01 Phase II trial will show results of ENHERTUpatients with NSCLC, including new data from the HER2-expressing cohort and data from the HER2 mutant cohort. Collaboration in the scientific community is critical to improving outcomes for patients. AstraZeneca is collaborating with Daiichi Sankyo Company, Limited (Daiichi Sankyo) to develop and commercialize ENHERTUand datopotamab deruxtecan globally. A late-breaking analysis from the ADAURA Phase III trial will underscore the practice changing results for adjuvant TAGRISSOin Stage IB-IIIA EGFRm NSCLC and show the disease-free survival results for patients who had been treated with adjuvant chemotherapy prior to TAGRISSOand those who were not by stage of disease. A second exploratory analysis from the Phase III ADAURA trial will highlight the impact of treatment with adjuvant TAGRISSOon quality of life based on patient-reported outcomes. TAGRISSOwas recently approved in the adjuvant setting in the US. The ongoing NeoADAURA Phase III trial testing the benefit of treating patients with resectable EGFRm NSCLC with neoadjuvant TAGRISSOwill be highlighted in a poster presentation. The MERMAID-1 Phase III trial testing IMFINZI in patients with completely resected, Stage II and III NSCLC who show evidence of minimal residual disease (MRD), will also be highlighted in a poster. MERMAID-1 is an early-stage NSCLC Phase III trial evaluating circulating tumor DNA measurements to monitor for MRD and to identify patients at high risk of recurrence after surgery who may benefit from intervention with immunotherapy. AstraZeneca will also present data from several trials exploring targeted therapies and novel combinations for advanced lung cancer, including: Additional data from the CASPIAN Phase III trial of IMFINZI in extensive-stage small cell lung cancer (ES-SCLC) showing exposure response and pharmacokinetics as well as exploratory analyses based on extent of disease The biomarker-directed HUDSON Phase II platform trial of IMFINZI in combination with LYNPARZA© (olaparib) and other novel anti-cancer medicines, including danvatirsen (STAT3 antisense oligonucleotide), ceralasertib (ATR inhibitor) and oleclumab (anti-CD73), in patients with NSCLC who progressed on anti-PD(L)1 therapy; The ODIN BM Phase I trial assessing TAGRISSObrain exposure in patients with EGFRm NSCLC central nervous system (CNS) metastases; The TATTON Phase Ib trial of TAGRISSOplus savolitinib in patients with EGFRm MET-overexpressed/amplified NSCLC; A trial-in-progress update on the Phase I trial of TAGRISSOin combination with patritumab deruxtecan (HER3-DXd; U3-1402) in patients with locally advanced or metastatic EGFRm NSCLC.